Hemochromatosis
Clinical Snapshot
Hemochromatosis is a disorder of iron regulation in which the body absorbs substantially more dietary iron than it needs, and the excess is progressively deposited in the liver, heart, pancreas, joints, skin, and anterior pituitary gland rather than being safely stored or excreted.[1] The great majority of cases are hereditary hemochromatosis, caused by mutations in the HFE gene on chromosome 6 — almost always homozygosity for the C282Y variant — which impairs the liver's ability to produce hepcidin, the hormone that normally restrains intestinal iron absorption and iron release from storage cells. With hepcidin deficient, the iron-export channel ferroportin stays abnormally active on both gut enterocytes and iron-recycling macrophages, so more iron is absorbed from every meal and more is released back into circulation than the body actually needs, year after year.[1]
A separate, distinct etiology worth naming clearly from the outset is secondary (acquired) iron overload — iron accumulation from repeated red blood cell transfusions (as in transfusion-dependent thalassemia, sickle cell disease, or myelodysplastic syndrome), from excessive parenteral or oral iron administration, or occasionally from a chronic liver disease that itself dysregulates iron handling. This is a genuinely different clinical problem: the iron loading is driven by an external source rather than a genetic absorption defect, and — as covered in Choose Initial Treatment — it changes which first-line therapy actually makes sense.[1]
Hereditary hemochromatosis is genuinely common, and genuinely relevant to Canadian practice. It is one of the most common inherited disorders in people of Northern European ancestry, and Liver Canada (formerly the Canadian Liver Foundation) estimates it affects roughly 1 in 327 Canadians.[2] Population studies more broadly put the C282Y-homozygous genotype at roughly 1 in 200 to 1 in 400 people of Northern European descent, with some populations — Ireland in particular — estimated even higher.[3]
The single most important nuance in this chapter, easy to miss and important not to: carrying the C282Y-homozygous genotype is not the same as having clinical disease. Longitudinal cohort data show that only about 38-50% of C282Y homozygotes ever develop an elevated serum ferritin, and only about 10-33% go on to develop clinical hemochromatosis with organ involvement — the remaining 75-90% with biochemical evidence of iron loading stay asymptomatic. Penetrance is also strongly sex-skewed: roughly 28% of male C282Y homozygotes develop clinical disease compared with roughly 1% of female homozygotes, largely because regular menstrual blood loss provides women a natural, ongoing iron-reduction mechanism until menopause.[1] This is why genetic confirmation alone does not automatically mean a treatment decision — see Assessment & Diagnosis and Treatment Targets.
Recognize the Condition
Because iron accumulates gradually over decades, hereditary hemochromatosis is classically diagnosed in a patient's 40s to 50s, with women typically presenting later than men for the menstrual-blood-loss reason noted above.[4] Earlier detection through opportunistic iron-panel screening means the florid late-stage picture below is now genuinely uncommon — most patients today are identified while still in the nonspecific or single-organ stage.[4]
Presentation by stage and organ system
A patient can present through any one of these, well before every system is involved — recognizing the pattern early, rather than waiting for the classic triad, is what actually catches the diagnosis in time to prevent organ damage.
Early, nonspecific
Fatigue, malaise, and arthralgia are the most common early complaints, and are exactly the kind of nonspecific symptoms that get attributed to something else for years before anyone checks an iron panel. Decreased libido, from early hypogonadal iron deposition, can also be an early clue.[4]
Hepatic
Hepatomegaly and asymptomatically elevated liver enzymes are often the first objective finding, sometimes picked up incidentally on routine bloodwork. Left undiagnosed, this progresses to fibrosis, cirrhosis, and an increased risk of hepatocellular carcinoma (see Red Flags & Refer).
Musculoskeletal and dermatologic
A distinctive arthropathy involving the second and third metacarpophalangeal joints — sometimes called the "iron fist" sign — along with chondrocalcinosis (pseudogout) is a genuinely useful clue, since it is an unusual joint distribution for ordinary osteoarthritis. Skin changes range from a subtle bronze or slate-grey hyperpigmentation (from combined melanin and iron deposition) to, in advanced untreated disease, frank bronzing.
Endocrine
Iron deposition in the pancreas can produce diabetes mellitus; iron deposition in the anterior pituitary can suppress gonadotropin release, causing hypogonadotropic hypogonadism — decreased libido, erectile dysfunction, or amenorrhea/infertility.
Cardiac
Iron deposition in the myocardium can cause a dilated or restrictive cardiomyopathy and conduction abnormalities, including atrial fibrillation — sometimes the presenting feature in an otherwise unexplained cardiomyopathy at a younger-than-expected age.
The historically taught "bronze diabetes" triad — skin hyperpigmentation, diabetes mellitus, and cirrhosis — describes advanced, longstanding, untreated disease. It is a useful teaching label, but it is now an uncommon presentation in practice precisely because earlier iron-panel screening catches most patients well before all three develop.[4]
Risk Factors
- C282Y homozygosity (two copies of the C282Y HFE variant) — accounts for roughly 80-100% of clinically recognized hereditary hemochromatosis in people of Northern European ancestry, and is the genotype the diagnostic and treatment pathways in this chapter are built around.[3]
- C282Y/H63D compound heterozygosity — a substantially milder genotype; fewer than about 11% of compound heterozygotes ever develop clinical iron overload, and disease when it occurs is typically driven by an additional cofactor (alcohol use, metabolic dysfunction-associated steatotic liver disease, viral hepatitis) rather than the genotype alone.[3]
- H63D homozygosity — generally does not cause clinically significant iron overload on its own in people of Northern European ancestry.[3]
- Rare non-HFE hereditary forms — juvenile hemochromatosis (HJV or HAMP mutations, causing severe iron overload and organ failure typically in the 20s-30s), and mutations in TFR2 or the ferroportin gene (SLC40A1). These are uncommon and generally need genetics/hepatology referral for confirmation once HFE testing is negative despite confirmed iron overload (see Assessment & Diagnosis).[1]
- Male sex — roughly 28% clinical penetrance in C282Y-homozygous men versus roughly 1% in C282Y-homozygous women, and men are typically diagnosed at a younger age since they lack the menstrual-blood-loss protection women have until menopause.[1]
- A first-degree relative with confirmed hereditary hemochromatosis — the single strongest reason to test even an asymptomatic person (see Non-Pharmacologic Treatment).[4]
- Northern European ancestry, particularly Irish, Scottish, English, or Scandinavian.[3][2]
- Cofactors that increase the likelihood or severity of clinical disease in a genetically susceptible person: significant alcohol use, viral hepatitis, and metabolic dysfunction-associated steatotic liver disease.
- Secondary (acquired) iron overload — a distinct, non-genetic risk pathway: repeated red blood cell transfusions (transfusion-dependent thalassemia, sickle cell disease, myelodysplastic syndrome), excessive medicinal iron intake, or certain chronic liver diseases. This population is managed differently — see Choose Initial Treatment and Special Populations.[1]
Red Flags & Refer
Complications of inadequately treated iron overload
Left undetected or untreated, progressive iron deposition can cause hepatic fibrosis, cirrhosis, and a meaningfully increased risk of hepatocellular carcinoma; dilated or restrictive cardiomyopathy and arrhythmia (particularly atrial fibrillation); diabetes mellitus from pancreatic iron deposition; hypogonadotropic hypogonadism from pituitary iron deposition; a distinctive arthropathy; and an increased susceptibility to certain iron-loving ("siderophilic") bacterial infections — most notably Vibrio vulnificus, but also Yersinia enterocolitica and Listeria monocytogenes — because these organisms grow markedly faster in iron-rich serum (see Non-Pharmacologic Treatment for the specific food-safety counseling this drives).
Escalate beyond routine phlebotomy management, to hepatology, cardiology, or endocrinology as appropriate, for any of the following:
- Signs of decompensated liver disease — jaundice, ascites, variceal bleeding, or worsening encephalopathy — in a patient with known or suspected hemochromatosis.
- A serum ferritin over 1000 ng/mL, which meaningfully raises the likelihood of bridging fibrosis or cirrhosis and should prompt hepatic fibrosis assessment (MRI-based iron/fibrosis quantification, or liver biopsy in selected cases) before or alongside starting phlebotomy — see Assessment & Diagnosis.[5]
- New-onset heart failure, arrhythmia (especially atrial fibrillation), or unexplained cardiomyopathy in a patient with known or suspected iron overload.
- New-onset diabetes mellitus in a patient with known or suspected hemochromatosis — pancreatic involvement is a marker of significant total-body iron burden.
- Any first-degree relative of a confirmed patient who has not yet been offered testing (see Non-Pharmacologic Treatment) — this is a genuinely easy step to lose track of.
The single biggest determinant of long-term outcome in this disease is timing. Patients who begin iron-reduction therapy before significant organ damage — particularly before cirrhosis or diabetes develops — can achieve a normal life expectancy; once cirrhosis is established, it does not reverse with successful iron depletion, and hepatocellular carcinoma surveillance becomes a lifelong necessity regardless of how well iron levels are subsequently controlled.[5]
Assessment & Diagnosis
Step 1 — transferrin saturation and ferritin
Fasting transferrin saturation (TS) is the most sensitive initial screening test and should be checked first; a TS of 45% or higher is the threshold that should prompt further workup.[5][4] Serum ferritin is checked alongside it — a level above roughly 300 ng/mL in men or 200 ng/mL in women is the commonly used threshold suggesting iron overload — but ferritin is also an acute-phase reactant, so an elevated level in isolation, especially without an elevated TS, should prompt consideration of inflammation, infection, malignancy, or metabolic dysfunction-associated steatotic liver disease as the actual cause before assuming iron overload.[4]
Step 2 — HFE genetic testing
An elevated TS and/or ferritin should be followed by HFE genetic testing for the C282Y and H63D variants. Population-wide genetic screening of asymptomatic people without an abnormal iron panel or a family history is not recommended.[4]
| Genotype | Clinical significance |
|---|---|
| C282Y/C282Y (homozygous) | The clinically significant genotype and the great majority of hereditary hemochromatosis cases. Still substantially incomplete penetrance — most homozygotes never develop clinical disease (see Clinical Snapshot). |
| C282Y/H63D (compound heterozygous) | Milder; fewer than about 11% develop clinical iron overload, usually only with an additional cofactor (alcohol, fatty liver, viral hepatitis). |
| H63D/H63D (homozygous) | Generally not associated with clinically significant iron overload alone. |
| Single C282Y or H63D copy (heterozygous carrier) | Not itself a cause of clinical iron overload; relevant mainly for family-planning and cascade-testing discussion. |
| HFE genotype-negative, iron overload confirmed | Consider a non-HFE hereditary cause (juvenile hemochromatosis, TFR2, ferroportin disease) or secondary/acquired iron overload; refer hepatology/genetics. |
Step 3 — assessing severity: MRI versus liver biopsy
For most patients, MRI-based hepatic iron quantification (R2*/T2*) has replaced liver biopsy as the preferred way to confirm and quantify hepatic iron loading noninvasively.[5] Liver biopsy is now reserved for a smaller group: patients with a ferritin over roughly 1000 ng/mL, persistently abnormal liver enzymes, or genuine diagnostic uncertainty, where directly assessing the degree of fibrosis or confirming cirrhosis changes management (see Red Flags & Refer and Monitoring & Follow-Up for the hepatocellular carcinoma surveillance this triggers).[5]
Differential diagnosis
Before attributing an elevated ferritin to hereditary hemochromatosis, consider: secondary iron overload (transfusion history, excess medicinal iron); ferritin elevation from inflammation, infection, or malignancy as an acute-phase reactant, independent of true iron overload; metabolic dysfunction-associated steatotic liver disease, which commonly causes a mildly elevated ferritin without true iron overload; alcohol-related liver disease; and porphyria cutanea tarda, which is associated with HFE mutations and iron overload in its own right. A normal or only mildly elevated TS with a markedly elevated ferritin should raise suspicion for one of these alternative causes rather than hereditary hemochromatosis.
Other investigations to complete the picture
Liver enzymes (baseline and to help decide on biopsy); fasting glucose or HbA1c to screen for pancreatic involvement; an ECG, with echocardiography if there are cardiac symptoms or signs; and, if hypogonadism is suspected clinically, testosterone with LH/FSH.
Treatment Targets
- Reduce total body iron burden to normal levels — the specific ferritin targets for the induction and maintenance phases of phlebotomy are detailed in Choose Initial Treatment.
- Prevent, or halt further progression of, iron-related organ damage (hepatic, cardiac, endocrine, articular).
- Achieve a normal life expectancy — genuinely achievable for a patient who begins treatment before significant organ damage, particularly before cirrhosis or diabetes develops; this is worth stating explicitly to a newly diagnosed patient, since the diagnosis can otherwise sound far more frightening than the realistic prognosis with timely treatment.[5]
- Manage any organ complications already present (diabetes, cardiomyopathy, arthropathy, hypogonadism) in parallel with iron reduction — iron already deposited does not reverse quickly, and some of these complications need their own dedicated management regardless of how well iron levels are subsequently controlled.
- For a patient in whom cirrhosis is already established: maintain lifelong hepatocellular carcinoma surveillance, since that risk persists even after iron stores are successfully normalized.[5]
- Complete first-degree relative cascade testing.
- Counsel on the specific dietary and food-safety measures that meaningfully reduce risk in this condition (see Non-Pharmacologic Treatment).
Choose Initial Treatment
Therapeutic phlebotomy is first-line treatment for essentially every patient with confirmed hereditary hemochromatosis and iron overload who can tolerate it. It is simple, highly effective, and markedly less expensive than any pharmacologic alternative — there is no drug that phlebotomy needs to prove superior to; it is simply the standard of care whenever a patient is eligible.[5][4]
Induction phase
Remove approximately 450-500 mL of whole blood weekly (twice weekly is sometimes used if well tolerated), adjusting frequency and volume based on tolerance. Check hemoglobin/hematocrit before each session — reduce the frequency or volume if it is dropping too quickly or the patient is symptomatic — and check serum ferritin monthly. Continue until ferritin reaches approximately 50 ng/mL; do not intentionally drive it lower, since that risks iatrogenic iron-deficiency anemia rather than any additional benefit.[4][5] Full induction commonly takes many months — occasionally over a year — of weekly treatment to reach target, and setting that expectation with the patient up front meaningfully helps adherence.[6]
Maintenance phase
Once the induction target is reached, reduce frequency to roughly every 2-4 months (about three to four sessions a year), with ferritin rechecked approximately every 6 months, keeping ferritin generally within the 50-100 ng/mL range. Maintenance phlebotomy is lifelong — iron reaccumulates if it stops, so this is not a course of treatment with a defined end date.[4][5]
A genuinely practical Canadian point: an otherwise-eligible hemochromatosis patient (normal hemoglobin, not on insulin, and meeting standard donor eligibility) can complete maintenance-phase phlebotomy as a regular Canadian Blood Services donation — every 56 days for men, every 84 days for women — rather than an outpatient hospital/clinic procedure. It is the same treatment, and the blood is used to help other patients rather than discarded; worth raising directly with any patient who has reached the maintenance phase.[6]
Phlebotomy adverse effects
Minor adverse effects — vasovagal reactions, local site bruising/hematoma, or transient fatigue — occur in a meaningful minority of patients and are usually manageable by adjusting volume or session frequency rather than stopping treatment.[4]
Chelation is not a routine alternative to phlebotomy — it carries a materially higher adverse-effect burden and is reserved, with specialist consultation, for patients who genuinely cannot use phlebotomy:[4]
- Significant anemia that phlebotomy would worsen.
- Cardiac instability that makes tolerating repeated volume removal unsafe.
- Poor venous access precluding reliable phlebotomy.
- Secondary/transfusion-dependent iron overload — patients receiving ongoing red blood cell transfusions for an underlying hematologic condition cannot have iron subtracted by phlebotomy without worsening the anemia the transfusions are treating; chelation is the appropriate first-line approach for this population specifically, not a fallback (see Special Populations).
Three agents are used, each with a distinct route and monitoring burden (full detail in Drug Tables): deferoxamine (parenteral, historically the first available agent), deferasirox (oral, the most commonly used first oral choice), and deferiprone (oral, reserved given its agranulocytosis risk and corresponding monitoring requirement).
Non-Pharmacologic Treatment
Dietary counseling
- Avoid iron supplements and multivitamins that contain iron — an obvious but easily overlooked source, especially in an over-the-counter multivitamin taken out of habit.[2]
- Limit vitamin C supplementation — vitamin C significantly enhances nonheme iron absorption and, in high doses, can mobilize tissue iron in a way that carries theoretical cardiotoxic risk in an iron-overloaded patient; a reasonable practical ceiling is under 500 mg per day, and vitamin C-containing supplements are best avoided outright rather than merely reduced.[4]
- Moderate, rather than eliminate, red meat and other heme-iron-rich foods — heme iron is absorbed considerably more efficiently than the nonheme iron in plant foods, so moderating intake meaningfully helps, even though dietary iron restriction alone is never sufficient treatment on its own.[4]
- Avoid or substantially limit alcohol — alcohol and iron overload act synergistically on the liver, and alcohol use significantly increases the risk of cirrhosis in a patient with hemochromatosis; this matters even more once any degree of fibrosis is already present.[4]
Avoid raw or undercooked shellfish and other raw seafood. This is a specific, easily overlooked, and genuinely important food-safety point: Vibrio vulnificus, a bacterium found in raw shellfish (classically raw oysters), grows dramatically faster in iron-rich serum than in normal blood, and infection in a person with iron overload can progress to severe septicemia with a case-fatality rate reported above 50% in high-risk individuals. The same iron-rich-serum mechanism raises susceptibility to Yersinia enterocolitica and Listeria monocytogenes as well, though the shellfish/Vibrio link is the single most important, specific point to counsel on directly.
Patient education
Hemochromatosis is a manageable, lifelong condition, not a life-limiting one, when treatment starts before significant organ damage — this reassurance is worth giving explicitly at diagnosis. Set the expectation up front that induction-phase phlebotomy is frequent (typically weekly) and can take many months to over a year to reach target, and that maintenance-phase phlebotomy continues indefinitely afterward — an easy point for a patient to misunderstand as a finite course of treatment.[4] Where the patient meets standard donor-eligibility criteria, mention that maintenance-phase phlebotomy can often be completed as a regular Canadian Blood Services donation rather than a hospital procedure (see Choose Initial Treatment).[6]
Family cascade screening
Hereditary hemochromatosis is inherited in an autosomal recessive pattern. Every first-degree relative of a confirmed C282Y-homozygous patient should be offered HFE genetic testing — if both parents of an index patient's sibling are carriers, each sibling has a 25% chance of being homozygous, a 50% chance of being a heterozygous carrier, and a 25% chance of inheriting neither variant. Testing does not need to start before adulthood (roughly age 18).[4][1] Counsel that a relative who tests homozygous still benefits meaningfully from knowing early, given the low but real penetrance and the fact that early detection — well before any symptoms develop — is exactly the scenario in which treatment achieves the best outcome (see Red Flags & Refer).
Special Populations
Pregnancy
Phlebotomy is generally avoided during pregnancy — normal pregnancy already increases iron demand and causes a degree of physiologic anemia, and standard iron-panel interpretation is altered by pregnancy itself. Iron-reduction treatment is typically deferred until postpartum in a patient without severe iron overload, with the treating specialist individualizing management for anyone with more significant disease.
Breastfeeding
No hemochromatosis-specific restriction applies to breastfeeding itself. Chelating agents have limited breastfeeding safety data and should be avoided unless a treating specialist judges the benefit clearly outweighs the uncertainty — phlebotomy, where otherwise appropriate, avoids this question entirely.
Pediatrics
Because iron accumulates gradually over decades, clinical HFE-related hereditary hemochromatosis essentially never presents in childhood. Juvenile hemochromatosis (caused by HJV or HAMP mutations) is a distinct, rare, more aggressive entity that typically causes severe cardiac and endocrine complications in the 20s-30s rather than in childhood itself, and needs pediatric/adult genetics and hepatology referral for confirmation and management rather than the HFE-based pathway in this chapter.[1]
Older adults
Continue phlebotomy as tolerated; older adults and those with cardiac comorbidity may tolerate large-volume removal less well, so individualize volume and frequency and watch more closely for vasovagal reactions and anemia during induction.
Renal and hepatic impairment
Adjust chelator dosing per the product monograph in renal impairment, particularly for deferasirox, which itself can raise serum creatinine and therefore needs closer renal monitoring in this population. Once cirrhosis is established, hepatocellular carcinoma surveillance is required indefinitely — see Monitoring & Follow-Up — regardless of how effectively iron levels are subsequently controlled.[5]
Secondary/transfusion-dependent iron overload
This population is managed differently from HFE-related hereditary hemochromatosis from the start: ongoing transfusion dependence for an underlying hematologic condition (transfusion-dependent thalassemia, sickle cell disease, myelodysplastic syndrome) means phlebotomy would worsen the anemia the transfusions are correcting, so chelation therapy is first-line here rather than a fallback reserved for phlebotomy-ineligible patients (see Choose Initial Treatment). Management is typically directed by the treating hematology team managing the underlying transfusion-dependent condition.[1]
Monitoring & Follow-Up
- Induction phase: hemoglobin/hematocrit before each phlebotomy session; serum ferritin monthly, to track progress toward the approximately 50 ng/mL induction target.[4]
- Maintenance phase: serum ferritin approximately every 6 months, adjusting phlebotomy frequency to keep it generally within the 50-100 ng/mL range; this continues for life.[4][5]
- Liver enzymes periodically, particularly for any patient who had an elevated ferritin or abnormal LFTs at diagnosis.
- Once cirrhosis is confirmed, hepatocellular carcinoma surveillance (ultrasound, with or without alpha-fetoprotein) approximately every 6 months, indefinitely — this risk does not go away once iron levels normalize, and losing track of ongoing surveillance once a patient feels well on maintenance phlebotomy is a genuine, avoidable error (see Common Errors to Avoid).[5]
- Periodic fasting glucose/HbA1c screening for pancreatic involvement, and cardiac follow-up (repeat ECG, echocardiography as indicated) for anyone with baseline cardiac involvement or symptoms.
- For a patient on chelation therapy: agent-specific monitoring — for deferiprone, weekly absolute neutrophil count for at least the first 6 months, then a reduced but ongoing frequency; for deferasirox, regular renal function/urinalysis, LFTs, and CBC; for deferoxamine, periodic audiometry and ophthalmologic examination.
- Confirm first-degree relative cascade testing has actually been completed, not just discussed once and left open.
Common Errors to Avoid
- Diagnosing iron overload from an isolated elevated ferritin without also checking transferrin saturation — ferritin alone is an acute-phase reactant and can be elevated for reasons that have nothing to do with iron overload.[4]
- Assuming a confirmed C282Y-homozygous genotype automatically means the patient has, or will develop, clinical disease — most homozygotes never do, and genotype alone is not itself a treatment decision (see Clinical Snapshot).[1]
- Starting iron chelation therapy as a first-line choice in a patient who is actually phlebotomy-eligible, rather than reserving it for genuine phlebotomy ineligibility or secondary/transfusion-dependent iron overload.
- Driving induction-phase ferritin below the roughly 50 ng/mL target, causing iatrogenic iron-deficiency anemia rather than any additional benefit.[4]
- Stopping phlebotomy once the induction target is reached instead of transitioning to lifelong maintenance-phase treatment.
- Not offering HFE genetic testing to first-degree relatives of a confirmed patient.[4]
- Treating secondary (transfusion- or medication-related) iron overload with phlebotomy rather than recognizing it as a distinct etiology generally requiring chelation instead.
- Losing track of hepatocellular carcinoma surveillance once cirrhosis has been identified, particularly once a patient is doing well on maintenance phlebotomy and iron levels look normal.[5]
- Not specifically counseling against raw or undercooked shellfish — a distinct, genuinely important point beyond the more obvious "avoid iron supplements" advice.
- Continuing a vitamin C supplement, or an iron-containing multivitamin taken out of habit, without anyone specifically asking about it at a medication review.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Therapeutic Phlebotomy — First-Line
Not a drug — the standard, preferred first-line intervention for essentially every phlebotomy-eligible patient. Simple, highly effective, and markedly less costly than any chelation alternative.
| Drug / intervention | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Therapeutic phlebotomy | Induction phase: Approximately 450-500 mL blood weekly (twice weekly if well tolerated) until serum ferritin reaches approximately 50 ng/mL; check ferritin monthly Maintenance phase: Every 2-4 months (roughly 3-4 times yearly), lifelong; recheck ferritin approximately every 6 months, keeping it generally within 50-100 ng/mL | Vasovagal reactions, local venipuncture-site bruising/hematoma, transient fatigue; iatrogenic iron-deficiency anemia if the induction target is overshot | None — a procedure, not a drug | Check hemoglobin/hematocrit before each session. Eligible patients (normal hemoglobin, not on insulin, meeting standard donor criteria) can often complete maintenance-phase treatment as a regular Canadian Blood Services donation rather than a hospital/clinic procedure.[4][6] |
Iron Chelation Therapy
Reserved for patients who cannot use phlebotomy (significant anemia, cardiac instability, poor venous access) or who have secondary/transfusion-dependent iron overload, where chelation is first-line rather than a fallback. Requires specialist consultation and initiation. Doses are adult doses and require patient-specific, product-monograph-confirmed titration.
| Drug / intervention | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Deferoxamine | Administration: Slow subcutaneous infusion (typically over several hours, several nights weekly) via portable pump, or continuous IV infusion for more urgent parenteral control — dose individualized to iron burden per product monograph | Ototoxicity and retinal toxicity (dose/duration-related — requires periodic audiometry and ophthalmologic examination), injection-site pain/reactions, hypotension or anaphylactoid reaction with rapid IV administration, rare pulmonary toxicity with high-dose IV use | Avoid concurrent high-dose vitamin C except under specialist direction — can worsen iron-related cardiotoxicity during active chelation | Reserved for patients needing parenteral chelation (e.g., secondary/transfusion-dependent iron overload) or intolerant of oral agents; practical outpatient use requires a portable infusion pump; never administer as a rapid IV push.[5] |
| Deferasirox | Administration: Once daily, oral, weight-based dosing titrated to serum ferritin trend per product monograph | Gastrointestinal disturbance (diarrhea, nausea, abdominal pain), skin rash, rising serum creatinine, hepatotoxicity, rare GI ulceration/hemorrhage | Increased nephrotoxicity risk with concurrent NSAIDs or other nephrotoxic agents | The most commonly used oral chelator. Requires baseline and periodic renal function/urinalysis, liver enzymes, and complete blood count monitoring; take per product labeling.[5] |
| Deferiprone | Administration: Divided oral doses per product monograph | Agranulocytosis/neutropenia (contraindicated with a history of recurrent neutropenia or agranulocytosis), gastrointestinal upset, arthralgia, zinc deficiency, transaminase elevation | Avoid combining with other agents independently associated with neutropenia where possible | Requires weekly absolute neutrophil count monitoring for at least the first 6 months of therapy, then reduced but ongoing frequency; hold immediately and recheck ANC for any sign of infection.[5] |
What to Avoid
Confirm neither of these is being taken, including inadvertently through a routine multivitamin, at every medication review.
| Drug / intervention | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Iron supplements (e.g., ferrous sulfate) | Use in hemochromatosis: Avoid unless independently indicated | Directly worsens iron overload | None specific — the interaction is the therapeutic effect itself, which is the problem in this population | Avoid unless a separate, independently confirmed iron-deficiency indication exists; check for an iron-containing multivitamin taken out of habit. |
| Vitamin C (ascorbic acid) supplements, high-dose | Use in hemochromatosis: Avoid, or strictly limit if used at all | Theoretical cardiotoxic risk in iron overload with high-dose supplementation, via mobilization of tissue iron | Enhances nonheme iron absorption from food when taken with meals | Avoid supplementation; keep total dietary vitamin C under roughly 500 mg/day if any supplementation is used at all.[4] |
References
- HFE-Related Hemochromatosis — GeneReviews, University of Washington, Seattle (Barton JC, Parker CJ). GeneReviews (NCBI Bookshelf NBK1440), updated 2024 Apr 11
- Hemochromatosis — Liver Canada (formerly the Canadian Liver Foundation). liver.ca, accessed 2026
- Genetics of Hereditary Hemochromatosis — British Columbia Medical Journal (Whittington C). BCMJ 2002;44(10):544-546
- Hereditary Hemochromatosis: Rapid Evidence Review — American Family Physician (Kane SF, Roberts C, Paulus R). Am Fam Physician 2021;104(3):263-270
- ACG Clinical Guideline: Hereditary Hemochromatosis — American College of Gastroenterology (Kowdley KV, Brown KE, Ahn J, Sundaram V). Am J Gastroenterol 2019;114(8):1202-1218
- Hemochromatosis and why blood loss can be a beneficial form of therapy — Canadian Blood Services. blood.ca, Research Education & Discovery
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.